Russell Alan J. - 05 Feb 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Scientific Officer, Director
Signature
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Issuer symbol
EWTX
Transactions as of
05 Feb 2025
Net transactions value
-$275,117
Form type
4
Filing time
07 Feb 2025, 16:38:15 UTC
Previous filing
31 Dec 2024
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $1,443 +8,015 +54% $0.1800 22,878 05 Feb 2025 Direct
transaction EWTX Common Stock Sale $240,623 -8,015 -35% $30.02 14,863 05 Feb 2025 Direct F1, F2
transaction EWTX Common Stock Options Exercise $216 +1,200 +8.1% $0.1800 16,063 06 Feb 2025 Direct
transaction EWTX Common Stock Sale $36,153 -1,200 -7.5% $30.13 14,863 06 Feb 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -8,015 -0.59% $0.000000 1,348,765 05 Feb 2025 Common Stock 8,015 $0.1800 Direct
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -1,200 -0.09% $0.000000 1,347,565 06 Feb 2025 Common Stock 1,200 $0.1800 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.0216, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.